Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) released its 19th annual Corporate Social Responsibility (CSR) report, detailing its 2019 achievements and actions in response to the 2020 global pandemic. Key highlights include 17% reduction in CO2 emissions per square foot, 85% solid waste diversion from landfills, and $7.5 million in philanthropic investments. Recognized as Barron’s no. 1 Most Sustainable Company for 2019, Agilent emphasizes environmental, social, and governance (ESG) strategies aimed at enhancing the quality of life globally.
Summary not available.
Agilent Technologies Inc. (NYSE: A) announces the adoption of its clinical informatics platform, Alissa Interpret, by the North West Genomic Laboratory Hub (NW GLH) in England. This platform enhances genomic testing capabilities by standardizing variant analysis and reporting on next-generation sequencing (NGS) data. Designed for efficiency, it integrates various genomic data types, supporting the interpretation of both rare diseases and cancer genomics. Agilent aims to improve diagnostic accuracy and reduce analysis time, addressing the growing demand for genomic testing solutions.
Agilent Technologies Inc. (NYSE: A) has unveiled its new Agilent 7850 ICP-MS System, designed to enhance productivity in ICP-MS analysis workflows. This innovative instrument features smart tools aimed at minimizing common time traps that can waste time and increase costs, particularly benefiting less experienced users in small to medium contract labs. The 7850's advanced software streamlines instrument setup and workflow, helping labs achieve high-quality results efficiently. With a revenue of $5.34 billion in fiscal 2020, Agilent continues to lead in the life sciences and diagnostics sector.
Agilent Technologies Inc. (NYSE: A) has launched the Biomarker Pathologist Training Program, aimed at enhancing the ability of pathologists to accurately score biomarkers. This global initiative, initially available in Europe and North America, leverages Agilent's expertise in companion diagnostics and partnerships with pharmaceutical firms. The program includes both basic and advanced training, offered digitally via Pathcore Scholar. It is designed to improve patient outcomes by ensuring high concordance in biomarker scoring, critical for the increasing prevalence of targeted therapies in oncology.
Agilent Technologies reported Q4 revenue of $1.48 billion, an 8% increase year-over-year, with GAAP net income of $222 million (71 cents per share). Non-GAAP net income reached $305 million (98 cents per share), surpassing last year's figures. The Life Sciences and Applied Markets Group posted $671 million in revenue, while the Diagnostics and Genomics Group generated $294 million. For fiscal year 2021, revenue is projected between $5.6 billion and $5.7 billion, with non-GAAP EPS guidance of $3.57 to $3.67.
Agilent Technologies Inc. (NYSE: A) launched the NanoDis System for nanoparticle dissolution testing, designed to ensure compliance with 21 CFR Part 11 regulations. Developed in collaboration with MyBiotech GmbH, this system enhances the efficiency of R&D and manufacturing workflows by providing an automated process for consistent QC of new drug formulations. The NanoDis System is recognized as a finalist for the CPhI Pharma Awards, highlighting its innovative role in advancing pharmaceutical quality control.
Agilent Technologies, Inc. (NYSE: A) has announced an increase in its quarterly dividend to 19.4 cents per share, reflecting an 8% rise over the previous quarter. The dividend payment is set for January 27, 2021, to shareholders on record as of January 5, 2021. Future dividend amounts are subject to board approval. Agilent continues to operate as a leader in life sciences, diagnostics, and applied chemical markets, generating $5.16 billion in revenue in fiscal 2019 and employing over 16,300 individuals globally.
Agilent Technologies (NYSE: A) has awarded the Agilent Thought Leader Award to professors Carl H. June and Michael Milone for their contributions to CAR T-cell cancer immunotherapy, notably the co-development of tisagenlecleucel (Kymriah™). The partnership aims to establish standards in cell-based cancer therapeutics through advanced CRISPR technology and Agilent's instruments such as the xCELLigence RTCA eSight and 6546 LC/Q-TOF Mass Spectrometer. This collaboration is expected to enhance cancer treatment methodologies and improve the quality of T-cell engineering.
Agilent Technologies (NYSE: A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx to help identify patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDA® (pembrolizumab). This assay is the only FDA-approved companion diagnostic for this purpose, enhancing the ability of pathologists to determine PD-L1 expression, a key biomarker for the therapy. With this approval, Agilent strengthens its role in drug/diagnostic co-development, marking the seventh cancer type for which the test has been approved.